Enhanced ex vivo buccal transport of propranolol: evaluation of phospholipids as permeation enhancers

Archives of Pharmacal Research

Volumn 26, Issue 5, 2003, Pages 421-425

  Lee, Jaehwi ^a,c   Choi, Young Wook ^b  

^a PURDUE UNIVERSITY   (United States)

^b Chung Ang University   (South Korea)

^c Akina Inc   (United States)

Author keywords

Buccal delivery; Didecanoylphosphatidylcholine; Lysophosphatidylcholine; Permeation enhancer; Propranolol; Sodium taurodihydrofusidate

Indexed keywords

EID: 27844520578     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02976701     Document Type: Article

References (30)

1. Anders, R. and Merkle, H. P., Evaluation of laminated mucoadhesive patches for buccal drug delivery. Int. J. Pharm., 49, 231-240 (1989).
2. Aungst, B. J., Rogers, N. J., and Shefter, E., Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter. J. Pharmacol. Exp. Ther., 24, 23-27 (1988).
3. Aungst, B. J. and Rogers, N. J., Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery. Int. J. Pharm., 53, 227-235 (1989).
4. Bolin, T., Franzen, L., Sjodahl, R., and Tagesson, C., Passage of molecules through the wall of the gastrointestinal tract. Scand. J. Gastroenterol., 21, 441-448 (1986).
5. Chidambaram, N. and Srivatsava, A. K., Buccal drug delivery systems. Drug Dev. Ind. Pharm., 21, 1009-1036 (1995).
6. Cid, E., Mella, F., Lucchini, L., Carcamo, M., and Monasterio, J., Plasma concentrations and bioavailability of propranolol by oral, rectal and intravenous administration in man. Biopharm. Drug Dispos., 7, 559-566 (1986).
7. Coutel-Egros, A., Maitani, Y., Veillard, M., Machida, Y., and Nagai, T., Combined effects of pH, cosolvent and penetration enhancers on the in vitro buccal absorption of propranolol through excised hamster cheek pouch. Int. J. Pharm., 84, 117-128 (1992).
8. DeGrande, G., Benes, L., Horrière, F., Karsenty, H., Lacoste, C., McQuinn, R., Gou, J.-H., and Scherrer, R., Specialized oral mucosal drug delivery systems: Patches, In Rathbone, M.J. (Eds.). Oral Mucosal Drug Delivery. Marcel Dekker, New York, pp. 285-317, (1996).
9. De Vries, M. E., Boddé, H. E., Verhoef, J. C., and Junginger, H. E., Developments in buccal drug delivery. Crit. Rev. Therap. Drug Carr. Syst., 8, 271-303 (1991).
10. Dowty, M. E., Knuth, K. E., Irons, B. K., and Robinson, J. R., Transport of thyrotropin releasing hormone in rabbit buccal mucosa in vitro. Pharm. Res., 9, 1113-1122 (1992).
11. Fisher, A. N., Farraj, N. F., OHagan, D. T., Jabbal-Gill, I., Johansen, B. R., Davis, S. S., and Illum, L., Effect of L-α-lysophosphatidylcholine on the nasal absorption of human growth hormone in three animal species. Int. J. Pharm., 74, 147-156 (1991).
12. Ganem-Quintanar, A., Kalia, Y. N., Falson-Rieg, F., and Buri, P., Mechanism of oral permeation enhancement. Int. J. Pharm., 156, 127-142 (1997).
13. Harris, D. and Robinson, J. R., Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci., 81, 1-10 (1992).
14. Hermens, W. A. J. J., Hooymans, P. M., Verhoef, J. C., and Merkus, F. W. H. M., Effects of absorption enhancers on human nasal tissue ciliary movement in vitro. Pharm. Res., 7, 144-146 (1990).
15. Hirai, S., Yashiki, T., and Mima, H., Effect of surfactants on the nasal absorption of insulin in rats. Int. J. Pharm., 9, 165-172 (1981).
16. Hovgaard, L., Brøndsted, H., and Nielsen, H. M., Drug delivery studies in Caco-2 monolayers. II. Absorption enhancer effects of lysophosphatidylcholines. Int. J. Pharm., 114, 141-149 (1995).
17. Iwamoto, K. and Watanabe, J., Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats. J. Pharm. Pharmacol., 37, 826-828 (1985).
18. Kissel, T., Drewe, J., Bantle, S., Rummelt, A., and Beglinger, C., Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. Pharm. Res., 9, 52-57 (1992).
19. Le Brun, P. P. H., Fox, P. L. A., De Vries, M. E., and Boddé, H. E., In vitro penetration of some b-adrenoreceptor blocking drugs through porcine buccal mucosa. Int. J. Pharm., 49, 141-145 (1989).
20. 5] enkephalin from liquid crystalline phases of glyceryl monooleate. Int. J. Pharm., 195, 35-38 (2000).
21. Lee, J., Lee, S. K., and Choi, Y. W., The effect of storage conditions on the permeability of porcine buccal mucosa. Arch. Pharm. Res., 25, 546-549 (2002).
22. nd edition). Pharmaceutical Press, London, (1999).
23. Richardson, J. L., Minhas, P. S., Thomas, N. W., and Illum, L., Vaginal administration of gentamicin to rats. Pharmaceutical and morphological studies using absorption enhancers. Int. J. Pharm., 56, 29-35 (1989).
24. Schürmann, W. and Turner, P., A membrane model of the human oral mucosa as derived from buccal absorption performance and physicochemical properties of the b-blocking drugs atenolol and propranolol. J. Pharm. Pharmacol., 30, 137-147 (1978).
25. Şenel, S. and Hincal, A. A., Drug permeation enhancement via buccal route: possibilities and limitations. J. Control. Rel., 72, 133-144 (2001).
26. Shand, D. G., Nickolis, E. M., and Oates, J. A., Plasma propranolol levels in adults with observation in four children. Clin. Pharmacol. Ther., 11, 112-118 (1970).
27. Vermehren, C. and Hansen, H. S., Shape changes in the erythrocyte membrane induced by the absorption enhancer didecanoylphosphatidylcholine. Int. J. Pharm., 174, 1-8 (1998).
28. Walle, T., Conradi, E. C., Walle, U. K., Fagan, T. C., and Gaffney, T. E., The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin. Pharmacol. Ther., 24, 668-677 (1978).
29. Wertz, P. W. and Squier, C. A., Cellular and molecular basis of barrier function in oral epithelium. Crit. Rev. Therap. Drug Carr. Syst., 8, 237-269 (1991).
30. Zhang, J., Niu, S., Ebert, C., and Stanley, T. H., An in vivo dog model for studying recovery kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage. Int. J. Pharm., 101, 15 22 (1994).